Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chemo-Immunotherapy: A New Trend in Cancer Treatment
Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González-Rodríguez, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2912-2912
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 33
Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen
Szu‐Ting Yang, Wen-Hsun Chang, Fang-Wei Chou, et al.
Taiwanese Journal of Obstetrics and Gynecology (2024) Vol. 63, Iss. 1, pp. 10-16
Open Access | Times Cited: 24
Cisplatin in the era of PARP inhibitors and immunotherapy
Mingrui Duan, Shuguang Leng, Peng Mao
Pharmacology & Therapeutics (2024) Vol. 258, pp. 108642-108642
Closed Access | Times Cited: 12
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Eleonora Ghisoni, Matteo Morotti, Apostolos Sarivalasis, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 12
Endoplasmic reticulum-targeted delivery of celastrol and PD-L1 siRNA for reinforcing immunogenic cell death and potentiating cancer immunotherapy
Jie Wang, Zilong Zhang, Yan Zhuo, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 8, pp. 3643-3660
Open Access | Times Cited: 11
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor‐Eliade Ciuleanu, Michael Schenker, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114296-114296
Open Access | Times Cited: 9
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Pankaj Kumar Garg, Siddhika Pareek, Prakash Kulkarni, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6537-6537
Open Access | Times Cited: 9
PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis
Francisco Cézar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Barbara Lins Silva, et al.
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access | Times Cited: 1
Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system
Kenny Misael Calvillo‐Rodríguez, Helen Yarimet Lorenzo-Anota, Cristina Rodrı́guez-Padilla, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer
Jagadeesh Rajaram, Lokesh Kumar Mende, Yaswanth Kuthati
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1120-1120
Open Access | Times Cited: 7
Nanostructured Drug Delivery Systems in Immunotherapy: An Updated Overview of Nanotechnology-Based Therapeutic Innovations
George-Alexandru Croitoru, Adelina-Gabriela Niculescu, Dragoș Epistatu, et al.
Applied Sciences (2024) Vol. 14, Iss. 19, pp. 8948-8948
Open Access | Times Cited: 7
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer
Longyong Xu, Fanglue Peng, Qin Luo, et al.
Cell (2024)
Closed Access | Times Cited: 7
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy
José L. Blaya-Cánovas, Carmen Griñán‐Lisón, Isabel Blancas, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance
Daosong Dong, Yu Xue, Jingjing Xu, et al.
Drug Resistance Updates (2024) Vol. 77, pp. 101125-101125
Closed Access | Times Cited: 6
Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications
Wei Mao, Hyuk Sang Yoo
Biomaterials Research (2024) Vol. 28
Open Access | Times Cited: 6
Neoadjuvant chemo-immunotherapy is improved with a novel pulsed electric field technology in an immune-cold murine model
Chiara Pastori, Ebtesam Nafie, Mukta Wagh, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0299499-e0299499
Open Access | Times Cited: 5
Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study
Pengfei Yu, Guangyu Ding, Xingmao Huang, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 4
Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
Yue Wang, Dhamotharan Pattarayan, Haozhe Huang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study
Jae-Sung Yoo, Ji Hoon Kim, Hee Sun Cho, et al.
Abdominal Radiology (2024) Vol. 49, Iss. 9, pp. 3127-3135
Closed Access | Times Cited: 4
“Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug”
Amanda R. Decker-Farrell, Stephen A. Sastra, Tetsuhiro Harimoto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Current Trends and Innovative Approaches in Cancer Immunotherapy
Jae-Chang Kim, Ruby Maharjan, Jonghyuck Park
AAPS PharmSciTech (2024) Vol. 25, Iss. 6
Closed Access | Times Cited: 4
Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells
Mahmoud Singer, Jennifer Valerin, Zhuoli Zhang, et al.
Cells (2025) Vol. 14, Iss. 3, pp. 166-166
Open Access
Tumor-Targeted Delivery of PD-1-Displaying Bacteriophages by Escherichia coli for Adjuvant Treatment of Colorectal Cancer
Hongrui Li, Ying Zhou, Bang‐Ce Ye
ACS Synthetic Biology (2025)
Closed Access
Interpretable Prediction of Lymphopenia Following Neo-Adjuvant Chemo-Radiotherapy for Rectal Cancer: An Analysis of the ARISTOTLE Randomised Phase III Trial
Ying Zhang, Douglas Brand, Sumeet Hindocha, et al.
(2025)
Closed Access
Role of liposomes in chemoimmunotherapy of Breast cancer
Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, et al.
Journal of drug targeting (2025), pp. 1-43
Closed Access
Page 1 - Next Page

Scroll to top